China Neuromodulation Devices Market Outlook to 2033 - Implantable Neuromodulation Devices and Non-Invasive Neuromodulation Devices

1.1 List of Tables
1.2 List of Figures

2.1 What Is This Report About?
2.2 Neuromodulation Devices Market Segmentation
2.3 Definitions of Markets Covered in the Report

3.1 Neuromodulation Devices Market, China, Revenue ($m), 2018-2033
3.1.1 Implantable Neuromodulation Devices Market, China, Revenue ($m), by Segment, 2018-2033
3.2 Neuromodulation Devices Market, China, Volume (Units), 2018-2033
3.2.1 Implantable Neuromodulation Devices Market, China, Volume (Units), by Segment, 2018-2033
3.3 Neuromodulation Devices Market, China, Average Price ($), 2018-2033
3.4 Neuromodulation Devices Market, China, Company Share by Revenue ($m), 2025

4.1 Boston Scientific Corp
4.1.1 Company Overview
4.2 Medtronic Plc
4.2.1 Company Overview
4.3 LivaNova Plc
4.3.1 Company Overview
4.4 Beijing Pins Medical Co Ltd
4.4.1 Company Overview
4.5 Abbott Laboratories
4.5.1 Company Overview
4.6 Enterra Medical Inc
4.6.1 Company Overview
4.7 B. Braun Melsungen AG
4.7.1 Company Overview

6.1 Corporate Communications
6.1.1 Oct 10, 2025: Nexalin Technology Attends the 2025 Maxim Growth Summit
6.2 Government and Public Interest
6.2.1 Nov 07, 2025: Empowering National Medical Device Innovation and Promoting Industry Integration
6.2.2 Oct 10, 2025: Nexalin Technology Attends the 2025 Maxim Growth Summit
6.3 Other Significant Developments
6.3.1 Nov 07, 2025: Empowering National Medical Device Innovation and Promoting Industry Integration
6.3.2 Sep 29, 2025: PolyU And Zhejiang Qiangnao Technology Sign MOU To Explore Joint Research Centre For Brain-Computer Interface
6.4 Product News
6.4.1 Nov 28, 2025: Yale-Trained Neuroscientist Introduces Panbrain Lume "Digital Sunshine" Device to Improve Sleep
6.4.2 Nov 05, 2025: Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for Alzheimer’s Treatment
6.4.3 Oct 30, 2025: Nexalin Technology Receives Regulatory Approval for Gen 2 SYNC Neurostimulation Device in Israel
6.4.4 Oct 21, 2025: Nexalin’s DIFS Neurostimulation Demonstrates Cognitive Improvements in Alzheimer’s and Dementia
6.4.5 Oct 08, 2025: Nexalin Technology Reports Positive Clinical Results for Alzheimer’s with Gen-2 SYNC Device
6.4.6 Sep 25, 2025: Nexalin Technology Issues U.S. Patent for HALO Clarity Device with DIFS Technology
6.5 Strategy And Business Planning
6.5.1 Nov 13, 2025: Nexalin Technology Appoints Carmi Masha Technologies Ltd. As Exclusive Distributor In Israel
6.5.2 Oct 30, 2025: Nexalin Technology Receives Regulatory Approval for Gen 2 SYNC Neurostimulation Device in Israel
6.5.3 Sep 29, 2025: PolyU And Zhejiang Qiangnao Technology Sign MOU To Explore Joint Research Centre For Brain-Computer Interface

7.1 Research Methodology
7.1.1 Coverage
7.1.2 Secondary Research
7.1.3 Primary Research
7.1.4 Market Modeling and Forecasting
7.1.5 Company Share Analysis
7.1.6 Benchmarking
7.2 the analyst Consulting
7.3 Contact the Publisher
7.4 Disclaimer

Table 1: Neuromodulation Devices Market, China, Revenue ($m), USD Constant, 2018-2033
Table 2: Implantable Neuromodulation Devices Market, China, Revenue ($m), USD Constant, 2018-2033
Table 3: Neuromodulation Devices Market, China, Volume (Units), 2018-2033
Table 4: Implantable Neuromodulation Devices Market, China, Volume (Units), 2018-2033
Table 5: Neuromodulation Devices Market, China, Average Price ($), 2018-2033
Table 6: Neuromodulation Devices Market, China, Company Share by Revenue ($m), 2025
Table 7: Neuromodulation Devices Market Pipeline Products
Table 8: Total Number of Primary Research Participants, Neurology Devices Market, by Country

Figure 1: Neuromodulation Devices Market, China, Revenue ($m), USD Constant, 2018-2033
Figure 2: Implantable Neuromodulation Devices Market, China, Revenue ($m), USD Constant, 2018-2033
Figure 3: Neuromodulation Devices Market, China, Volume (Units), 2018-2033
Figure 4: Implantable Neuromodulation Devices Market, China, Volume (Units), 2018-2033
Figure 5: Neuromodulation Devices Market, China, Company Share (%), 2025